Introduction of a modular automated voltage-clamp platform and its correlation with manual human ether-à-go-go related gene voltage-clamp data

Assay and Drug Development Technologies

Volumn 9, Issue 6, 2011, Pages 600-607

  Scheel, Olaf ^a   Himmel, Herbert ^b   Rascher Eggstein, Gesa ^a   Knott, Thomas ^a  

^a Cytocentrics AG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ASTEMIZOLE; BAY 09; BAY 10; BAY 11; BAY 12; BAY 13; BAY 14; BAY 15; BAY 16; BAY 17; BAY 18; CHEMICAL COMPOUND; CISAPRIDE; DOFETILIDE; METOPROLOL; POTASSIUM CHANNEL; QUINIDINE; TERFENADINE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SAFETY; DRUG SCREENING; GENE; HUMAN; HUMAN CELL; IC 50; KIDNEY CELL; PATCH CLAMP; PHYSICAL CHEMISTRY; VOLTAGE CLAMP;

ACTION POTENTIALS; AUTOMATION, LABORATORY; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; SOFTWARE;

EID: 80555130144     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2010.0352     Document Type: Article

References (23)

1. Hille B: Ion Channels of Excitable Membranes, Third edition. Sinauer Associates, Inc. Sunderland, MA, 2001.
2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov 2006;5:993-996. (Pubitemid 44835126)
3. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
4. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM: Multiple mechanisms in the long-QT syndrome. Circulation 1996;94:1996-2012.
5. Sanguinetti MC, Jiang C, Curran ME, Keating MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
6. Sanguinetti MC, Curran ME, Spector PS, Keating MT: Spectrum of HERG K F-channel dysfunction in an inherited cardiac arrhythmia. PNAS 1996;93; 2208-2212. (Pubitemid 26079907)
7. Roy M-L, Dumaine R, Brown AM: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996;94: 817-823. (Pubitemid 26289240)
8. Taglialatela M, Castaldo P, Pannaccione A, Giorgio G, Genovese A, Marone G, Annunziato L: Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 1999;29:182-189. (Pubitemid 29333355)
9. Cavero I, Mestre M, Guillon JM, Crumb W: Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000;1:947-973.
10. Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R: High-throughput electrophysiology: an emerging paradigm for ion channel screening and physiology. Nat Rev Drug Discov 2008;7:358-368.
11. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflueg Arch 1981;391:85-100. (Pubitemid 11012976)
12. Kiss L, Bennett PB, Uebele VN, Koblan KS, Kane SA, Neagle B, Schroeder K: High throughput ion channel pharmacology: planar array based voltage clamp. Assay Drug Dev Technol 2003;1:127-135.
13. Dubin AE, Nasser N, Rohrbacher J, Hermans AN, Marrannes R, Grantham C, van Rossem K, Cik M, Chaplan SR, Gallacher D, Xu J, Guia A, Byrne NG, Mathes C: Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J Biomol Screen 2005;10:168-181.
14. Bridgland-Taylor MH, Hargreaves AC, Easter A, Orme A, Henthorn DC, Ding M, Davis AM, Small BG, Heapy CG, Abi-Gerges N, Persson F, Jacobson I, Sullivan M, Albertson N, Hammond TG, Sullivan E, Valentin JP, Pollard CE: Optimisation and validation of a medium-throughput electrophysiologybased hERG assay using IonWorks HT. J Pharmacol Toxicol Methods 2006; 54:189-199. (Pubitemid 44308866)
15. Nattel S, Duker G, Carlsson L: Model systems for the discovery and development of antiarrhythmic drugs. Prog Biophys Mol Biol 2008;98:328-339.
16. Farre C, Haythornthwaite A, Haarmann C, Stoelzle S, Kreir M, George M, Brüggemann A, Fertig N: Port-a-Patch and Patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. Comb Chem High Throughput Screen 2009;12:24-37.
17. Mathes C, Friis S, Finley M, Liu Y: Qpatch: the missing link between HTS and ion channel drug discovery. Comb Chem High Throughput Screen 2009;12:78-95.
18. Stett A, Burkhardt C, Weber U, van Stiphout P, Knott T: Cytocentering: a novel technique enabling automated cell-by-cell patch clamping with the CytoPatcḧchip. Receptors Channels 2003;9:59-66. (Pubitemid 36372593)
19. German Patent 10 2007 010 843.7-09
20. Zhou ZF, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT: Properties of hERG channels stably expressed in HEK293 cells studied at physiological temperature. Biophys J 1998;74:230-241. (Pubitemid 28041752)
21. Himmel HM: Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential. J Pharmacol Toxicol Methods 2007;56:145-158. (Pubitemid 47376970)
22. Guo L, Guthrie H: Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Methods 2005;52: 123-135. (Pubitemid 41008636)
23. Ertl P, Rohde B, Selzer P: Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000;43:3714-3717.